Kalaris Therapeutics (NASDAQ:KLRS) Releases Earnings Results, Beats Expectations By $0.06 EPS

Kalaris Therapeutics (NASDAQ:KLRS) announced its quarterly earnings data on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.06, FiscalAI reports.

Kalaris Therapeutics Stock Performance

Shares of NASDAQ:KLRS traded up $0.34 during trading on Thursday, hitting $5.17. The company’s stock had a trading volume of 147,278 shares, compared to its average volume of 76,884. Kalaris Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $11.88. The business has a 50 day moving average price of $6.66 and a two-hundred day moving average price of $7.52. The company has a market capitalization of $118.86 million, a PE ratio of -2.40 and a beta of 0.15.

Wall Street Analysts Forecast Growth

KLRS has been the topic of a number of analyst reports. Citizens Jmp reduced their price objective on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Morgan Stanley began coverage on Kalaris Therapeutics in a research note on Thursday, April 16th. They issued an “overweight” rating and a $14.00 target price for the company. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Wedbush assumed coverage on shares of Kalaris Therapeutics in a research report on Thursday. They set an “outperform” rating and a $17.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Kalaris Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $15.60.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nano Cap New Millennium Growth Fund L P purchased a new stake in Kalaris Therapeutics during the 4th quarter worth about $34,000. Barclays PLC acquired a new position in shares of Kalaris Therapeutics during the fourth quarter worth about $51,000. Johnson Financial Group Inc. acquired a new position in shares of Kalaris Therapeutics during the third quarter worth about $58,000. XTX Topco Ltd purchased a new stake in shares of Kalaris Therapeutics during the second quarter worth approximately $65,000. Finally, WealthTrust Asset Management LLC acquired a new stake in Kalaris Therapeutics in the first quarter valued at approximately $72,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.